About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Egln1tm1Kael
targeted mutation 1, William G Kaelin
MGI:3777476
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Egln1tm1Kael/Egln1tm1Kael
Tg(CAG-cre/Esr1*)5Amc/0
involves: 129S6/SvEvTac * C57BL/6 * CBA MGI:3793292
cn2
Egln1tm1Kael/Egln1tm1Kael
Egln3tm1Vlcg/Egln3tm1Vlcg
Tg(Myh6-cre)2182Mds/0
involves: 129S6/SvEvTac * FVB/N MGI:5304713
cn3
Egln1tm1Kael/Egln1tm1Kael
Tg(Myh6-cre)2182Mds/0
involves: 129S6/SvEvTac * FVB/N MGI:5304715


Genotype
MGI:3793292
cn1
Allelic
Composition
Egln1tm1Kael/Egln1tm1Kael
Tg(CAG-cre/Esr1*)5Amc/0
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Egln1tm1Kael mutation (1 available); any Egln1 mutation (21 available)
Tg(CAG-cre/Esr1*)5Amc mutation (9 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mutants exposed to tamoxifen at E17.5 and 3 weeks after birth to induce cre expression begin dying suddenly around 10 weeks of age

growth/size/body
• by 10 weeks of age, mutants that are exposed to tamoxifen at E17.5 and 3 weeks after birth, are smaller

cardiovascular system
• 8- to 10-week old mutants treated with tamoxifen at E17.5 and 3 weeks after birth exhibit venous congestion
• the space between myocardial fibers is increased in mutants treated with tamoxifen at E17.5 and 3 weeks after birth
• cardiomyocytes of mutants treated with tamoxifen at E17.5 and 3 weeks after birth are enlarged, with occasional large nuclei
• mutants treated with tamoxifen at E17.5 and 3 weeks after birth consistently exhibit dilated cardiomyopathy
• mutants treated with tamoxifen at E17.5 and 3 weeks after birth exhibit increased contraction band necrosis indicative of early cardiac ischemia
• retroperitoneal hemorrhage is observed by 10 weeks of age in mutants exposed to tamoxifen at E17.5 and 3 weeks after birth

hematopoietic system
• mutants treated with tamoxifen at E17.5 and 3 weeks after birth show profound increases in red blood cell production associated with increased serum erythropoietin levels

muscle
• the space between myocardial fibers is increased in mutants treated with tamoxifen at E17.5 and 3 weeks after birth
• cardiomyocytes of mutants treated with tamoxifen at E17.5 and 3 weeks after birth are enlarged, with occasional large nuclei
• mutants treated with tamoxifen at E17.5 and 3 weeks after birth consistently exhibit dilated cardiomyopathy

integument
• by 10 weeks of age, mutants that are exposed to tamoxifen at E17.5 and 3 weeks after birth are erythematous and begin dying suddenly

homeostasis/metabolism
• mutants treated with tamoxifen at E17.5 and 3 weeks after birth show profound increases in red blood cell production associated with increased serum erythropoietin levels




Genotype
MGI:5304713
cn2
Allelic
Composition
Egln1tm1Kael/Egln1tm1Kael
Egln3tm1Vlcg/Egln3tm1Vlcg
Tg(Myh6-cre)2182Mds/0
Genetic
Background
involves: 129S6/SvEvTac * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Egln1tm1Kael mutation (1 available); any Egln1 mutation (21 available)
Egln3tm1Vlcg mutation (0 available); any Egln3 mutation (24 available)
Tg(Myh6-cre)2182Mds mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mean survival is 29 weeks

cardiovascular system
• at 5 weeks and severe at 8 weeks
• at 8 weeks, mice exhibit reduced left ventricular wall thickness and increased left ventricular end-diastolic dimension compared with control mice
• at 5 weeks and severe at 8 weeks
• severe at 8 weeks of age

muscle
• at 5 weeks and severe at 8 weeks
• severe at 8 weeks of age

cellular
• myocytes exhibit mitochondrial loss

growth/size/body
• at 5 weeks and severe at 8 weeks

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
cardiomyopathy DOID:0050700 J:179490




Genotype
MGI:5304715
cn3
Allelic
Composition
Egln1tm1Kael/Egln1tm1Kael
Tg(Myh6-cre)2182Mds/0
Genetic
Background
involves: 129S6/SvEvTac * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Egln1tm1Kael mutation (1 available); any Egln1 mutation (21 available)
Tg(Myh6-cre)2182Mds mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• following thoracic aorta constriction, liver wet weight to dry weight is increased compared to in wild-type mice
• following thoracic aorta constriction, lung wet weight to dry weight is increased compared to in wild-type mice
• following thoracic aorta constriction, mice exhibit myocyte dropout with replacement and interstitial fibrosis
• following thoracic aorta constriction
• following thoracic aorta constriction
• following thoracic aorta constriction, mice exhibit increased left ventricular end-diastolic dimension compared with control mice
• aged mice exhibit left ventricular posterior wall thickness compared with control mice
• following thoracic aorta constriction
• following thoracic aorta constriction or left anterior descending artery and in aged mice
• following thoracic aorta constriction, mice exhibit increased cardiac hypertrophy, reduced cardiac function (decreased fractional shortening and increased left ventricular end-diastolic dimension and left ventricular posterior wall thickness), increased heart weight, cardiac interstitial fibrosis, enlarge myocardial fiber, and congestion in the lung and liver compared with wild-type mice

muscle
• following thoracic aorta constriction, mice exhibit myocyte dropout with replacement and interstitial fibrosis
• following thoracic aorta constriction or left anterior descending artery and in aged mice

homeostasis/metabolism
• following thoracic aorta constriction, mice exhibit increased cardiac hypertrophy, reduced cardiac function (decreased fractional shortening and increased left ventricular end-diastolic dimension and left ventricular posterior wall thickness), increased heart weight, cardiac interstitial fibrosis, enlarge myocardial fiber, and congestion in the lung and liver compared with wild-type mice

liver/biliary system
• following thoracic aorta constriction, liver wet weight to dry weight is increased compared to in wild-type mice

respiratory system
• following thoracic aorta constriction, lung wet weight to dry weight is increased compared to in wild-type mice

cellular
• following thoracic aorta constriction
• myocytes exhibit mitochondrial loss

growth/size/body
• following thoracic aorta constriction
• following thoracic aorta constriction





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/23/2024
MGI 6.23
The Jackson Laboratory